<DOC>
	<DOCNO>NCT01129674</DOCNO>
	<brief_summary>The primary purpose study help answer follow research question : How LY 2140023 tolerate patient Schizophrenia compare standard care treatment 52 week time period . Whether LY 2140023 help patient Schizophrenia .</brief_summary>
	<brief_title>A Long-Term , Open-Label , Study Schizophrenia</brief_title>
	<detailed_description>The study include 2 treatment period . Study Period I begin patient randomization ( enrollment Study HBBO ) continue first 2 year treatment . Study Period II patient randomize treatment LY2140023 , begin patient complete second year treatment . Patients qualify enrollment randomize 3:1 ratio ( LY2140023 versus standard care , respectively ) 2 treatment group : flexible , twice-daily dose LY2140023 standard-of-care ( olanzapine , risperidone , aripiprazole , quetiapine ) . Those assigned LY2140023 option continue LY2140023 2 year deem appropriate investigator .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Must meet entry criterion , complete , acute , placebocontrolled clinical trial LY2140023 ( Study H8YMCHBBM , acute , placebocontrolled LY2140023 study allow protocols study ) . Female patient childbearing potential must agree use single , effective , medically acceptable method birth control . Patients must consider reliable level understanding sufficient perform test examination require protocol . Patients must able understand nature study give informed consent . Are currently enrol , discontinue within last 30 day clinical trial involve investigational product nonapproved use drug device ( LY2140023 ) , concurrently enrol type medical research judge scientifically medically compatible study . Patients treatment olanzapine , risperidone , aripiprazole , quetiapine , LY2140023 , specify protocol , relatively absolutely clinically contraindicate . Patients receive treatment clozapine dose great 200 mg daily within 12 month prior study enrollment , receive clozapine month study enrollment . Patients require concomitant treatment medication primary central nervous system activity , allow study protocol . Patients risk suicide . Patients diagnose substance dependence substance abuse within 6 month prior study enrollment . Patients diagnose substanceinduced psychosis within 7 day study enrollment time study . Female patient pregnant , nursing , lactate intend become pregnant within 30 day complete study . Have know glaucoma . Have history type seizure . Have seizure liability inconsistent exclusion criterion complete acute feeder study . Patients electroconvulsive therapy ( ECT ) within 3 month study enrollment ECT time study . Patients know Human Immunodeficiency Virus positive ( HIV+ ) status . Patients serious disease , recent stroke , heart , liver , kidney , lung blood diseases Patients Parkinson 's disease Are incapable participate study unwilling engage meaningful way study participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>